AMGN · News · 20260923N
Revenue Performance and Mix
AMGEN INC · 2026-09-23 · Importance 32 · Surprise 6 · In source text
Amgen reported approximately $10.1 billion of revenue in the second quarter. Newer products Repatha and EVENITY were reported to be offsetting declines from older medicines affected by patent expirations. The same report cited approximately $3.5 billion of second-quarter free cash flow, indicating substantial cash generation alongside the reported revenue mix shift.
Key facts
- Amgen reported Q2 revenue of $10.1 billion and free cash flow of $3.5 billion. source
- Amgen announced a quarterly dividend of $2.52 per share. source
- Envestnet Asset Management increased its stake in Amgen by 19.2% during the second quarter, acquiring an additional 326,260 shares. source
- New products Repatha and EVENITY are successfully offsetting declines from older drugs due to patent expirations. source
- Amgen's stock recently surpassed $410. source
- There was insider selling of Amgen shares by senior vice presidents reported in the filing referenced by MarketBeat. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | — | Amgen reported Q2 revenue of $10.1 billion and free cash flow of $3.5 billion. |
| cash | positive | realized | — | Amgen reported Q2 revenue of $10.1 billion and free cash flow of $3.5 billion. |
| liability | negative | committed | — | Amgen announced a quarterly dividend of $2.52 per share. |
| cash | negative | committed | — | Amgen announced a quarterly dividend of $2.52 per share. |